Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis?

TY - JOUR

T1 - Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis?

AU - Horn, Paul

AU - Newsome, Philip N.

N1 - Funding Information: This paper presents independent research funded (or supported) by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Declaration of personal interests: Dr Newsome reports consultancy or speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Gilead, Pfizer, Affimmune, Intercept, Johnson & Johnson, Novo Nordisk, Shire and Poxel Pharmaceuticals. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk.

PY - 2020/4/27

Y1 - 2020/4/27

UR - https://doi.org/10.1111/apt.15682

U2 - 10.1111/apt.15682

DO - 10.1111/apt.15682

M3 - Editorial

SN - 0269-2813

VL - 51

SP - 987

EP - 988

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 10

ER -